Literature DB >> 33135190

The momentous role of N6-methyladenosine in lung cancer.

Ruiyao Xu1, Gaozong Pang1, Qing Zhao1, Lin Yang1, Shu Chen1, Long Jiang2, Yuxian Shen1, Wei Shao1.   

Abstract

Lung cancer is the leading cause of cancer death worldwide. Although diagnostic methods and targeted drugs have been rapidly developed in recent years, the underlying molecular mechanisms in the pathogenesis of lung cancer remain enigmatic. The N6-methyladenosine (m6 A) modification is the most common modification of messenger RNA in eukaryotes and plays critical roles in many diseases, especially cancers. Ectopic m6 A modification is associated with human carcinogenesis, including lung cancer. The m6 A modification is mediated by methyltransferases (writers) and demethylases (erasers) and indirectly affects biological processes through the recruitment of specific reader proteins (readers). Many studies have shown that m6 A writers, erasers, and readers serve as specific and sensitive biomarkers for lung cancer diagnosis, prognosis, and therapy. This review summarizes recent studies on the biological functions of the m6 A modification in lung cancer and discusses the potential application of m6 A regulators in lung cancer diagnosis and therapeutics.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  RNA methylation; epitranscriptome; lung cancer; m6A; posttranscriptional modification

Year:  2020        PMID: 33135190     DOI: 10.1002/jcp.30136

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  11 in total

Review 1.  The roles of histone variants in fine-tuning chromatin organization and function.

Authors:  Sara Martire; Laura A Banaszynski
Journal:  Nat Rev Mol Cell Biol       Date:  2020-07-14       Impact factor: 94.444

2.  A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.

Authors:  Xuewen Wang; Chengfei Zhao; Dandan Huang; Zhoujie Liu; Mengmeng Liu; Fei Lin; Yingyu Lu; Jing Jia; Liqing Lin; Xinhua Lin; Huangyuan Li; Zhiwei Chen
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  m6A Topological Transition Coupled to Developmental Regulation of Gene Expression During Mammalian Tissue Development.

Authors:  Shanshan Li; Qing Yang; Rui Jiao; Pengfei Xu; Yazhou Sun; Xin Li
Journal:  Front Cell Dev Biol       Date:  2022-07-05

4.  m6A regulator-mediated RNA methylation modification patterns and immune microenvironment infiltration characterization in severe asthma.

Authors:  Deyang Sun; Huan Yang; Liming Fan; Fenglin Shen; Zhen Wang
Journal:  J Cell Mol Med       Date:  2021-10-14       Impact factor: 5.310

5.  A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma.

Authors:  Wenhao Ouyang; Yupeng Jiang; Shiyi Bu; Tiantian Tang; Linjie Huang; Ming Chen; Yujie Tan; Qiyun Ou; Luhui Mao; Yingjie Mai; Herui Yao; Yunfang Yu; Xiaoling Lin
Journal:  Front Cell Dev Biol       Date:  2022-01-24

Review 6.  The role of m6A methylation in osteosarcoma biological processes and its potential clinical value.

Authors:  Yanjiao Wu; Zhiyun Wang; Jianlin Shen; Wei Yan; Shurong Xiang; Huan Liu; Wenhua Huang
Journal:  Hum Genomics       Date:  2022-04-18       Impact factor: 6.481

7.  Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.

Authors:  Chen Gao; Ning Kong; Fan Zhang; Liuzhi Zhou; Maosheng Xu; Linyu Wu
Journal:  BMC Bioinformatics       Date:  2022-08-08       Impact factor: 3.307

8.  Comprehensive Analysis of Immune Cell Infiltration of m6a-Related lncRNA in Lung Squamous Cell Carcinoma and Construction of Relevant Prognostic Models.

Authors:  Pengfei Zhang; Huawei Li; Xiaoguang Cheng; Wei Wang
Journal:  Biomed Res Int       Date:  2022-07-14       Impact factor: 3.246

Review 9.  m6A RNA Methylation in Systemic Autoimmune Diseases-A New Target for Epigenetic-Based Therapy?

Authors:  Anna Wardowska
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-05

10.  MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis.

Authors:  Shan Hu; Peng Cao; Kangle Kong; Peng Han; Yu Deng; Fan Li; Bo Zhao
Journal:  J Transl Med       Date:  2021-05-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.